By the CDMOWorld Editorial Team | October 10, 2025
SPOKANE, Wash. / NOIDA, India — In a major step forward for U.S.-based pharmaceutical manufacturing, Jubilant HollisterStier LLC (JHS), a leading North American CDMO specializing in sterile injectables, has successfully launched a new high-speed, isolator-based fill-finish line at its Spokane, Washington facility. The milestone marks the completion of the company’s third production line at the site and the start of commercial production, following the successful manufacture of its inaugural batch.
Part of a US$132 million investment, the new line increases the Spokane facility’s sterile injectable capacity by 50%, significantly strengthening Jubilant HollisterStier’s ability to support complex and high-volume manufacturing programs for global pharma innovators. The new line’s advanced isolator technology enhances sterility assurance, throughput, and operational precision — all in compliance with top global regulatory standards.
“Launching our Third Line is more than a milestone—it’s a defining moment in Jubilant HollisterStier’s journey,” said Chris Preti, CEO, CDMO Sterile Injectables. “With this expansion, and a Fourth Line on the way, we’re not just doubling capacity — we’re building a future that strengthens the U.S. supply chain, creates jobs, and reaffirms our commitment to technological excellence and patient care.”
Once its fourth production line becomes operational, Jubilant HollisterStier expects to double its total sterile injectable output at Spokane. The company’s ongoing investments reinforce its leadership in onshore U.S. pharmaceutical production — a key focus amid new U.S. tariff measures and growing demand from multinational pharma companies seeking high-quality domestic manufacturing capacity.
JHS reports strong commercial interest in the new line, with a surge in Requests for Proposals (RFPs) from top-tier pharma partners and full utilization anticipated within three years. The company currently partners with five of the top 20 global pharma companies, maintaining an impressive 92% customer retention rate — a testament to its reliability and regulatory excellence.
Jubilant HollisterStier’s facilities are approved by global health authorities including the U.S. FDA, EMA, PMDA (Japan), Health Canada, and ANVISA (Brazil), among others, allowing it to serve customers in more than 140 countries.
About Jubilant HollisterStier LLC
Jubilant HollisterStier LLC, a wholly owned subsidiary of Jubilant Pharmova Limited, is a leading Contract Development and Manufacturing Organization (CDMO) focused on sterile injectables, lyophilization, and ophthalmic manufacturing. With advanced facilities in Spokane, Washington and Montréal, Québec, JHS provides full-service, regulatory-compliant solutions to accelerate speed to market while ensuring product quality and patient safety.
About Jubilant Pharmova Limited
Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a global life sciences company with businesses spanning Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO, Generics, and Novel Drug Development. Headquartered in India with a team of over 5,500 professionals worldwide, Jubilant operates manufacturing facilities and research centers across the U.S., Canada, Europe, and India.
About CDMOWorld
CDMOWorld is a digital publication dedicated to the global contract development and manufacturing industry, spotlighting innovation, investment, and collaboration shaping the future of outsourced biopharma and pharmaceutical production. We deliver coverage that connects CDMOs, innovators, and investors around the world. Visit www.CDMOWorld.com or contact info@cdmoworld.com to share your company news or insights.
